🏥 health
STAT+: Gilead to buy Arcellx in nearly $8B deal
Gilead Sciences is buying Arcellx in a deal worth $7. 8 billion, picking up its partner on a CAR-T therapy for multiple myeloma.
What’s Happening
So get this: Gilead Sciences is buying Arcellx in a deal worth $7.
8 billion, picking up its partner on a CAR-T therapy for multiple myeloma. (shocking, we know)
Why This Matters
Health experts are weighing in on what this means for people.
Medical professionals are taking note of this development.
The Bottom Line
This story is still developing, and we’ll keep you updated as more info drops.
Is this a W or an L? You decide.
Daily briefing
Get the next useful briefing
If this story was worth your time, the next one should be too. Get the daily briefing in one clean email.
Reader reaction
